European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017)
- Peter W. Hellings1, 2,
- David Borrelli3,
- Sirpa Pietikainen4,
- Ioana Agache5,
- Cezmi Akdis6, 7,
- Claus Bachert8,
- Michael Bewick9,
- Erna Botjes10,
- Jannis Constantinidis11,
- Wytske Fokkens2,
- Tari Haahtela12,
- Claire Hopkins13,
- Maddalena Illario14,
- Guy Joos15,
- Valerie Lund16,
- Antonella Muraro17,
- Benoit Pugin18,
- Sven Seys18, 19,
- David Somekh20,
- Pär Stjärne21,
- Arunas Valiulis22, 23,
- Erkka Valovirta24 and
- Jean Bousquet25, 26, 27Email author
© The Author(s) 2017
Received: 23 October 2017
Accepted: 15 December 2017
Published: 27 December 2017
On March 29, 2017, a European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases (CRD) was organized by the European Forum for Research and Education in Allergy and Airway Diseases. The event took place in the European Parliament of Brussels and was hosted by MEP David Borrelli and MEP Sirpa Pietikainen. The aim of the Summit was to correspond to the needs of the European Commission and of patients suffering from CRD to join forces in Europe for the prevention and self-management. Delegates of the European Rhinologic Society, European Respiratory Society, European Academy of Allergy and Clinical Immunology, European Academy of Paediatrics, and European Patients Organization EFA all lectured on their vision and action plan to join forces in achieving adequate prevention and self-management of CRD in the context of Precision Medicine. Recent data highlight the preventive capacity of education on optimal care pathways for CRD. Self-management and patient empowerment can be achieved by novel educational on-line materials and by novel mobile health tools enabling patients and doctors to monitor and optimally treat CRDs based on the level of control. This report summarizes the contributions of the representatives of different European academic stakeholders in the field of CRD.
To better understand genetic determinants, environmental factors, molecular and cellular mechanisms underlying CRDs.
To investigate social and economic factors leading to the onset, persistence and severity of CRDs.
To phenotype and endotype patients, allowing implementation of the key pillars of Precision Medicine, i.e. personalized care, participation of the patient, prediction of success of treatment and prevention of disease.
To develop unbiased and accurate biomarkers for multimorbidities, severity and follow-up of patients.
To propose novel care pathways including multimorbidity and self-management strategies.
To implement the principles of Precision Medicine into daily practice, in particular in primary care.
To coach self-empowered patients through novel mobile health tools.
To implement integrated care pathways with uniform information and treatment strategies provided by different care providers seen by patients.
A multidisciplinary practical platform with all stakeholders involved in CRD is currently missing. A symposium at the EU Parliament in October 2015  proposed that the implementation of Precision Medicine into clinical practice may help to achieve the arrest of the epidemic of allergies and CRD. Participants underscored the need for optimal patient care in Europe, supporting joint action plans for disease prevention, patient empowerment, and cost-effective treatment strategies . In the meantime, EUFOREA elaborated a European consensus report on the guidance of clinicians into the implementation of the principles of PM in daily practise .
The vision, mission and objectives of EUFOREA
EUFOREA is an international non-profit organisation forming an alliance of all stakeholders from national and international organizations, institutions, and agencies working towards the common vision of preventing and improving the burden of asthma, allergic airway diseases and CRS. EUFOREA proposes to reduce the preventable and avoidable burden of morbidity and disability due to CRD by means of a multidisciplinary practical approach with all stakeholders at national, regional and global levels. Its aim is for populations to reach the highest attainable standards of health and productivity at every age and for CRD to no longer present as a barrier to well-being or socio-economic development. Given the novel scientific data on the prediction and prevention of allergic and airway diseases, the cost of inaction is unacceptable and there is an urgent need to undertake integrated actions in Europe, joining forces in a multi-specialty way with all stakeholders.
To better educate the patients, the (para)medical community and the public
To develop innovative care pathways including the key principles of Precision Medicine, i.e. prevention, personalized care, prediction and participation
To empower the patients at the centre of the strategy, and to promote self-management and primary care
To educate patients and health care providers on the optimal care pathways for CRD, taking into account 4 approaches: prevention, prediction, participation and personalized care
To make recommendations of simple strategies for chronic airway disease management using emerging technologies for predictive medicine
To promote active and healthy ageing
To improve the work productivity of chronic airway disease sufferers
To improve the well-being of chronic airway disease sufferers
To reduce health and social inequities
To support academic research in Europe in the field of CRD through a unique research support platform.
The added value of EUFOREA is to develop a unique strategic partnership for the prevention and control of CRD in order to tackle all components of prevention and to combat CRD from basic science to policies. EUFOREA provides a network through which collaborating parties can combine their strengths, thereby achieving major results that no one single partner could obtain alone. EUFOREA is meeting the need for a pan-European multi-stakeholder platform for the development of optimal and integrated care pathways for CRD, through a coordinated research and education activity portfolio. The EUFOREA platform unites educational and research initiatives of all relevant stakeholders dealing with CRD through representatives of their official organizations: Primary Care physicians, Paediatricians and Allergologists via EAACI (European Academy of Allergy and Clinical Immunology), Respiratory physicians via ERS (European Respiratory Society), ENT doctors via ERS (European Rhinology Society), Allergy specialists of the ARIA (Allergic Rhinitis and its Impact on Asthma) expert group, Rhinologists of the EPOS expert committee, Patient organizations via EFA (European Federation of Allergy and Asthma Patient Organization), and Pharmacists via PGEU (Pharmaceutical Group at the European Parliament). The EUFOREA platform is unique given the multi-specialty nature and high academic profile of the multi-specialty advisory board taking part in the educational and clinical research activities of EUFOREA.
EUFOREA attempts to improve coordination between existing EU, governmental and non-governmental programmes to avoid duplication of efforts and wasting of resources.
Action plan of EUFOREA
ARIA Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
To propose a new AR classification,
To promote the concept of multi-morbidity in asthma and rhinitis, and
To develop guidelines with all stakeholders that could be used globally for all countries and populations, in particular developing countries.
EUFOREA mobile application ‘mySinusitisCoach’ CRS as a model for optimal patient coaching and empowerment
European CRS patient days to explore the needs and obstacles in current CRS care, including feedback on the mySinusitisCoach prototype using emerging technologies and the proposal of CRS interactive educational materials.
- 2.European meeting to align the patients’ needs and KOL vision on the mySinusitisCoach prototype (Fig. 4), with feedback on the unique educational and coaching strategy of the CRS patients by mySinusitisCoach.
Preparation of the implementation of mySinusitisCoach in several regions in Europe with the support of local governmental authorities.
Analyses of the data generated by mySinusitisCoach, showing socio-economic value, secondary and tertiary prevention of CRD
Deployment of mySinusitisCoach in Europe, with data on real-life burden and cost of disease, (in)effective current treatment strategies, and demonstration of the major benefit of the instalment of mySinusitisCoach for the patient and the society.
EUFOREA Educational Platform: a practical approach
EUFOREA Respiratory Research Platform for defining the RESEARCH NEEDS AND PRIORITIES in Europe
In November 2016, brainstorming sessions were held during the European Rhinology Research Forum (ERRF) on the research needs and priorities in the field of CRD with active participants from all over Europe. The major unmet needs and research priorities in the field of allergic rhinitis and Chronic Respiratory Diseases were highlighted from the perspectives of the patients and clinicians. This meeting resulted in the definition of the research priorities in the field of CRD and the joint action plan to meet these priorities . A follow-up meeting is planned in the Royal Academy of Medicine of Belgium in Brussels on November 9 and 10, 2017, involving basic researchers, clinicians, representatives of patient organizations, and representatives of the industry and health authorities.
The role of scientific societies
European scientific societies are crucial in the management of CRD. They provide evidence-based, state-of-the art guidance for health practitioners by means of publishing research and knowledge including clinical practice guidelines, statements and technical standards as well as by providing continuing medical education (CME). In addition, the large-scale annual or bi-annual congresses aim at transferring the latest scientific data to the clinicians. They bridge the gap between science and policy and advocate for policies committed to protecting public health. Scientific societies need to provide evidence-based input to ensure that airway diseases and their management is at the centre of policy decisions including air quality, European medical research, tobacco control and other preventative approaches such as occupational health issues. In conjunction with EFA, EAACI is currently launching a political Call to Action on Allergy and Asthma, with the support of the Interest Group on Allergy and Asthma of the European Parliament, led by the Finnish MEP Sirpa Pietikainen.
Prevention of allergy and asthma in Finland
In the early 1990s, the new paradigm of asthma as an inflammatory disease was implemented into practice by the Finnish Asthma Programme 1994–2004. This improved care and cut costs both for individual patients and society . New information of immune development in modern, urban societies has challenged the conventional thinking of allergy prevention. The Finnish Allergy Programme 2008–2018 was initiated to turn avoidance strategy into tolerance strategy, and to take a step from treatment to prevention [22, 23]. Focusing on severe allergies and emphasizing allergy health rather than mild problems also targeted the use of health-care resources more efficiently. Revisiting of the asthma and allergy paradigms has led to actions relevant to society and health-care as a whole. In the Finnish society, burden of these conditions has started to decline . The experience encourages medical communities and societies to lessen disability and costs caused by allergy and asthma and to improve public health.
Therapeutic strategies to prevent asthma
Asthma often starts early in life and tends to persist across the life cycle [2, 25]. Thus, asthma prevention is a continuum from conception (or even before) to old age, integrating the complex network of risk factors (genome, exposome and disease endotypes and phenotypes) into a detailed roadmap for action . Today the projection of children’s diseases in adulthood is the key target for research and prerequisite of effective prevention as well as healthy ageing . Wheezing is the major problem in both developed and developing countries affecting up to 50% of children under the age of 6 years. Even transient early wheeze is not only characterized by lower lung function but is also associated with chronic obstructive pulmonary disease in late adulthood . An important work point is to protect children from active and passive smoking. Speed networking and new technologies based e-research allow different projects to be integrated as well as the building of roads to modern paediatric respiratory medicine in EU countries .
A step-wise pathway is proposed: the tomorrow action plan relies on the multi-strategy approach focused on primary prevention and including the targeted hygiene concept. The 5-year programme relies on the wide use of health information technology translating vast amounts of “real-world” data unbiased by any pre-selection criteria into real-time clinical decision support at the point of care and harmonised disease management based on quality criteria . The 10-year strategy integrates the multi-strategy approach with big data into personalised prevention plans . Global, multi-discipline partnerships, rethinking healthcare, agreeing and implementing a fair balance between research and political priorities are all key points for an efficient asthma prevention strategy .
Immunologic rationale for prevention of CRD
Dysregulated immune system, exposure to pollutants, irritants and allergens at home or to professional irritants in the work environment [33, 34], schools and workplace, genetic factors, and respiratory infections all play a role in the increased prevalence of CRD [35, 36]. Tobacco smoke is a key factor in the development and progression of CRD. Activation of the immune system cells and their interaction with tissue cells followed by chronic inflammation is a key mechanism in their pathogenesis. A defect in allergen tolerance is the cause of allergic diseases and is based on immunologic mechanisms. Recently, leakiness in the epithelial barrier is a major finding in all Chronic Respiratory Diseases such as asthma, AR and CRS [37, 38]. Several strategies are being developed to prevent respiratory diseases, including the restoration of barrier deficiency. Identification of risk groups and early intervention to restore the barrier function are essential for successful prevention strategies [39–41].
A specific novel promising asthma prevention strategy resulted from the national survey in the United Kingdom
A prospective audit including more than 3 000 UK CRS surgical patients and assessing outcomes over a 5 year period showed significant improvement in the vast majority of patients . Patients were then stratified by onset of symptoms to surgery into early (< 1 years), mid (1–5 years) and late (> 5 years) cohorts. This showed that the percentage change from baseline of CRS outcomes (SNOT22 scores) was greater in the early than in the late cohort at all time points (p < 0.005 at 1 years) when other demographic factors and extent of surgery were controlled . Asthma prevalence was significantly higher in the late group, suggesting that earlier sinus surgery is associated with better outcomes in both the upper and lower respiratory tract, altering natural history and preventing co-morbidities.
Strategies for broad implementation of effective self-care
PROSTEP (Promotion of self-care in chronic diseases in the EU) is a tender designed to explore the added value of self-management in chronic diseases. It benefits from a thorough analysis of patient empowerment, including the relationship between self-management, joint decision-making and health literacy. PROSTEP stemmed from the EMPATHiE project (Empowering patients in the management of chronic diseases http://www.eu-patient.eu/whatwedo/Projects/EMPATHiE/), the first of two previous tenders, and from the experience of a platform of experts addressing the issues around the promotion of self-care in minor and self-limiting conditions (the PiSCE project). The overall requirements of this tender were (1) to conduct a study (consisting of a literature review and cost–benefit analysis) and (2) to set up a platform of experts in self-care in the field of chronic diseases to explore and propose possible methods of promotion of self-care for chronic diseases, taking into account previous and on-going policy work in this field such as the work of the CHRODIS JA. The 2-year project kicked off in January 2016.
The European Federation for Allergy and Airways Diseases Patients’ Associations (EFA) has launched different projects at EU level to empower patients. They are built on three pillars: education, self-management and advocacy. One of the projects, Hey Ya, aims at improving health literacy in adolescent patients via raising self-awareness, confidence and attitude. This is particularly important in teenagers in whom poor adherence due to reduced health literacy is one of the major contributors to uncontrolled allergic airway disease. Secondly, the My Air Coach project was launched by the help of the Horizon 2020 Research and Innovation framework programme with the aim to develop a patient-friendly, sensor-based tool to collect clinical, environmental and behavioural data relating to the patient. Via self-management, it is a powerful tool for the prevention of complications. mHealth technology, jointly with patients’ personal experience, are important for raising self-efficiency. Both Hey Ya and My Air Coach are important tools for improving teenagers’ approach toward the diseases. Lastly, EFA supports and actively participates in advocacy campaigns at EU level. Recently, the Written Declaration on Chronic Respiratory Diseases was closed and signed by 115 MEPs. A new ‘United Action for Allergy and Asthma’ was launched in the EU parliament in April 2017 to improve public policies. It addresses allergy and asthma and supports patients’ rights.
Technology transfer in rhinitis and asthma
The European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) includes 74 Reference Sites. Scaling up is an essential component of the Action Plan B3 of the EIP on AHA (chronic diseases and remote monitoring) [27, 44]. A transfer innovation from an App developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference sites will compare the phenotypic characteristics of rhinitis and asthma in adults and old age people using validated ICT tools (Allergy Diary  and CARAT: Control of Allergic Rhinitis and Asthma Test ) in 25 Reference Sites or regions across Europe. The aim is to better understand, assess the burden, diagnose and manage rhinitis and asthma in old age people.
The high prevalence and major socio-economic impact of CRD require an inter-academic and multi-stakeholder approach for the successful implementation of prevention strategies leading to cost savings and reduction of burden. EUFOREA will continue its’ mission to call for action by all stakeholders to implement Precision Medicine as the tool to arrest the epidemic of CRD. In Europe, there is an urgent need to join forces in the education of patients and medical care providers on prevention strategies, and to call for political action supported by all European academic stakeholders involved in the care of CRD.
All authors participated to the European Parliament meeting and to the writing of the paper. They all agreed on the contents of the paper. All authors read and approved the final manuscript.
Pr Bousquet reports personal fees and other from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, other from Kyomed, outside the submitted work. Dr Joos reports grants, personal fees and non-financial support from AstraZeneca; grants and personal fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis ; personal fees from Sandoz, Teva, Mundipharma outside the submitted work. Dr Hopkins reports non-financial support from Fiagon, personal fees from GSK, Entellus, Medtronic, Optinose, outside the submitted work. Dr. Seys reports personal fees from Mylan, outside the submitted work. The remaning authors declare that they have no conflicts of interests.
Ethics approval and consent to participate
Funding was provided by Euforea.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- 2008–2013 Action plan for the global strategy for the prevention and control of non communicable diseases. Prevent and control cardiovascular diseases, cancers, Chronic Respiratory Diseases, diabetes. 2008. http://www.who.int/nmh/Actionplan-PC-NCD-2008.pdf.
- Bousquet J, Anto JM, Berkouk K, Gergen P, Antunes JP, Augé P, et al. Developmental determinants in non-communicable chronic diseases and ageing. Thorax. 2015;70(6):595–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Samoliński B, Fronczak A, Włodarczyk A, Bousquet J. Council of the European Union conclusions on Chronic Respiratory Diseases in children. Lancet. 2012;379(9822):e45–6.View ArticlePubMedGoogle Scholar
- Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J, Bockelbrink A, et al. Chronic rhinosinusitis in Europe-an underestimated disease. A GA2LEN study. Allergy. 2011;66(9):1216–23.View ArticlePubMedGoogle Scholar
- Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67(1):91–8.View ArticlePubMedGoogle Scholar
- Samoliński B, Fronczak A, Kuna P, Akdis CA, Anto JM, Bialoszewski AZ, et al. Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. Allergy. 2012;67(6):726–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Council conclusions on prevention, early diagnosis and treatment of Chronic Respiratory Diseases in children: 31st EMPLOYMENT, SOCIAL POLICY, HEALTH and CONSUMER AFFAIRS Council meeting Brussels, 1 and 2 December 2011. Council of the European Union. 2011. http://www.consilium.europa.eu/.
- Bousquet J, Tanasescu CC, Camuzat T, Anto JM, Blasi F, Neou A, et al. Impact of early diagnosis and control of Chronic Respiratory Diseases on active and healthy ageing. A debate at the European Union Parliament. Allergy. 2013;68(5):555–61.View ArticlePubMedGoogle Scholar
- Muraro A, Fokkens WJ, Pietikainen S, Borrelli D, Agache I, Bousquet J, et al. European symposium on precision medicine in allergy and airways diseases: report of the European Union parliament symposium (October 14, 2015). Allergy. 2016;71(5):583–7.View ArticlePubMedGoogle Scholar
- Bousquet J, Dahl R, Khaltaev N. Global alliance against Chronic Respiratory Diseases. Allergy. 2007;62(3):216–23.View ArticlePubMedGoogle Scholar
- Bousquet J, Jorgensen C, Dauzat M, Cesario A, Camuzat T, Bourret R, et al. Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies. Curr Pharm Des. 2014;20(38):5928–44.View ArticlePubMedGoogle Scholar
- Hellings PW, Fokkens WJ, Akdis C, Bachert C, Cingi C, Dietz de Loos D, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy. 2013;68(1):1–7.View ArticlePubMedGoogle Scholar
- Hellings PW, Fokkens WJ, Bachert C, Akdis CA, Bieber T, Agache I, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis: an EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017. https://doi.org/10.1111/all.13162.Google Scholar
- Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):147–334.View ArticleGoogle Scholar
- Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.View ArticlePubMedGoogle Scholar
- Bousquet J, Schünemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130(5):1049–62.View ArticlePubMedGoogle Scholar
- Bousquet J, Mercier J, Avignon A, Bourret R, Camuzat T. MACVIA-LR (France) case study. Report EUR 27150 EN. In: Strategic intelligence monitor on personal health systems Phase 3 (SIMPHS3) JRC94487 Luxembourg: Publications Office of the European Union: JRC (Joint Research Centre) Science and policy report. Abadie F, editor. 2015. https://ec.europa.eu/jrc.
- Bousquet J, Schunemann HJ, Fonseca J, Samolinski B, Bachert C, Canonica GW, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70(11):1372–92.View ArticlePubMedGoogle Scholar
- Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016;6:47.View ArticlePubMedPubMed CentralGoogle Scholar
- Hellings P, Akdis C, Bachert C, Bousquet J, Pugin B. EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology. 2017;55:202.PubMedGoogle Scholar
- Haahtela T, Herse F, Karjalainen J, Klaukka T, Linna M, Leskelä R-L, et al. The Finnish experience to save asthma costs by improving care in 1987–2013. J Allergy Clin Immunol. 2017;139(2):408–14.View ArticlePubMedGoogle Scholar
- Haahtela T, von Hertzen L, Mäkelä M, Hannuksela M, Allergy Programme Working Group. Finnish Allergy Programme 2008–2018–time to act and change the course. Allergy. 2008;63(6):634–45.View ArticlePubMedGoogle Scholar
- von Hertzen LC, Savolainen J, Hannuksela M, Klaukka T, Lauerma A, Mäkelä MJ, et al. Scientific rationale for the Finnish Allergy Programme 2008–2018: emphasis on prevention and endorsing tolerance. Allergy. 2009;64(5):678–701.View ArticleGoogle Scholar
- Haahtela T, Valovirta E, Bousquet J, Mäkelä M, Allergy Programme Steering Group. The Finnish Allergy Programme 2008–2018 works. Eur Respir J. 2017. https://doi.org/10.1183/13993003.00470-2017.Google Scholar
- Duijts L, Reiss IK, Brusselle G, de Jongste JC. Early origins of chronic obstructive lung diseases across the life course. Eur J Epidemiol. 2014;29(12):871–85.View ArticlePubMedGoogle Scholar
- Bloomfield SF, Rook GA, Scott EA, Shanahan F, Stanwell-Smith R, Turner P. Time to abandon the hygiene hypothesis: new perspectives on allergic disease, the human microbiome, infectious disease prevention and the role of targeted hygiene. Perspect Public Health. 2016;136(4):213–24.View ArticlePubMedPubMed CentralGoogle Scholar
- Bousquet J, Barbara C, Bateman E, Bel E, Bewick M, Chavannes NH, et al. AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. Eur Respir J. 2016;47(4):1028–33.View ArticlePubMedGoogle Scholar
- Kerkhof M, Boezen HM, Granell R, Wijga AH, Brunekreef B, Smit HA, et al. Transient early wheeze and lung function in early childhood associated with chronic obstructive pulmonary disease genes. J Allergy Clin Immunol. 2014;133(1):68–76.View ArticlePubMedGoogle Scholar
- Hadjipanayis A, Stiris T, Del Torso S, Mercier J-C, Valiulis A, Ludvigsson J. Europe needs to protect children and youths against secondhand smoke. Eur J Pediatr. 2017;176(1):145–6.View ArticlePubMedGoogle Scholar
- Blumenthal D. Stimulating the adoption of health information technology. N Engl J Med. 2009;360(15):1477–9.View ArticlePubMedGoogle Scholar
- Agache I, Akdis CA. Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. Allergol Int. 2016;65(3):243–52.View ArticlePubMedGoogle Scholar
- Guilleminault L, Ouksel H, Belleguic C, Le Guen Y, Germaud P, Desfleurs E, et al. Personalised medicine in asthma: from curative to preventive medicine. Eur Respir Rev. 2017;26(143):160010.View ArticlePubMedGoogle Scholar
- Hox V, Steelant B, Fokkens W, Nemery B, Hellings PW. Occupational upper airway disease: how work affects the nose. Allergy. 2014;69(3):282–91.View ArticlePubMedGoogle Scholar
- Hox V, Delrue S, Scheers H, Adams E, Keirsbilck S, Jorissen M, et al. Negative impact of occupational exposure on surgical outcome in patients with rhinosinusitis. Allergy. 2012;67(4):560–5.View ArticlePubMedGoogle Scholar
- European Academy of Allergy and Clinical Immunology. Global atlas of asthma. Zurich: European Academy of Allergy and Clinical Immunology; 2013.Google Scholar
- European Academy of Allergy and Clinical Immunology. Global atlas of allergic rhinitis and chronic rhinosinusitis. Zurich: European Academy of Allergy and Clinical Immunology; 2014.Google Scholar
- Steelant B, Farré R, Wawrzyniak P, Belmans J, Dekimpe E, Vanheel H, et al. Impaired barrier function in patients with house dust mite–induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. J Allergy Clin Immunol. 2016;137(4):1043–53.View ArticlePubMedGoogle Scholar
- Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4. J Allergy Clin Immunol. 2012;130(5):1087–96.View ArticlePubMedGoogle Scholar
- Muraro A, Lemanske RF, Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2016;137(5):1347–58.View ArticlePubMedGoogle Scholar
- Canonica GW, Bachert C, Hellings P, Ryan D, Valovirta E, Wickman M, et al. Allergen Immunotherapy (AIT): a prototype of precision medicine. World Allergy Organ J. 2015;8(1):31.View ArticlePubMedPubMed CentralGoogle Scholar
- Galli SJ. Toward precision medicine and health: opportunities and challenges in allergic diseases. J Allergy Clin Immunol. 2016;137(5):1289–300.View ArticlePubMedPubMed CentralGoogle Scholar
- Browne JP, Hopkins C, Slack R, Topham J, Reeves B, Lund V, et al. Health-related quality of life after polypectomy with and without additional surgery. Laryngoscope. 2006;116(2):297–302.View ArticlePubMedGoogle Scholar
- Hopkins C, Rimmer J, Lund VJ. Does time to endoscopic sinus surgery impact outcomes in chronic rhinosinusitis? Prospective findings from the National Comparative Audit of Surgery for Nasal Polyposis and Chronic Rhinosinusitis. Rhinology. 2015;53(1):10–7.PubMedGoogle Scholar
- Bousquet J, Farrell J, Crooks G, Hellings P, Bel EH, Bewick M, et al. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). Clin Transl Allergy. 2016;6:29.View ArticlePubMedPubMed CentralGoogle Scholar
- Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Azevedo L, Sa-Sousa A, Branco-Ferreira M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. Allergy. 2010;65(8):1042–8.View ArticlePubMedGoogle Scholar